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The present report is a review ofdata assuming an etiological relationship between pelvic in-
flammatory disease (PID) and Mycoplasma hominis. Thus the organism can be isolated from
the vagina/cervix more frequently in PID patients than in any other clinical group, i.e., in half
to three-fourths of all such cases. One-fourth of PID patients develop a significant antibody
response to M. hominis during the course ofthe disease. The antibody response can be detected
by indirect hemagglutination tests. Grivet monkeys infected experimentally with M. hominis
develop PID, predominantly parametritis; the infection seems to spread via lymphatics to the
parametria. These animals develop a significant antibody response. The animals, like naturally
infected women, develop a marked increase in the serum level of lgM. In tissue cell cultures of
human fallopian tubes experimentally infected with M. hominis, a decrease of the mucociliary
wave activity occurs.
So far, few clinical data support an etiological role for Ureaplasma urealyticum in PID. In
grivet monkeys, the organism does not produce PID.
INTRODUCTION
Pelvic inflammatory disease (PID) is increasingly common. This increase seems to
be the result of the pandemic situation with regard to sexually transmitted diseases
(STD) that has prevailed in recent years in several developing countries. Sterility as a
sequelae to PID [1] has reached such proportions that it has even begun to influence
the population structure.
The etiology of PID is multifactorial. Approximately 15 percent of PID cases in
western industrial countries are associated with iatrogenic measures, such as inser-
tion of an intrauterine contraceptive device (IUD) [2]. Most of the remaining cases
seem to be "venereal" in origin, that is, occurring as an STD [3]. Also among
"iatrogenic" PID cases, however, such agents can be the cause of PID, as they often
occur in asymptomatic carriers, including women consulting for birth control.
Chlamydia trachomatis and Neisseria gonorrhoeae are among the most common
causative agents of PID. Anaerobic bacteria seem to be more often associated with
PID in some geographic areas than in others (cf. [4]). Mycoplasma hominis, or
pleuropneumonia-like organisms (PPLO), have also been considered an etiological
agent of PID [4,5,6,7,8,9,10,11,12,13,14,15,16,17], though the proportion of such
cases is, however, still not clear.
The present study discusses the current knowledge concerning PID associated
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with M. hominis and Ureaplasma urealyticum. The occurrence ofthese organisms in
the lower female genital tract is also briefly considered.
OCCURRENCE OF MYCOPLASMA HOMINIS AND UREAPLASMA
UREALYTICUM IN THE LOWER FEMALE GENITAL TRACT
Mycoplasma hominis
The first human isolate of mycoplasma was made as early as 1937 by Dienes and
Edsall [18] in pus from a Bartholin's gland abscess. The strain seems to have been a
strain ofM. hominis. This species was named in 1956 by Edward and Freundt [19].
M. hominis represents the vast majority of isolates of "classic" or large colony-
forming mycoplasmas from the genital tract (cf. [20]).
M. hominis has been found in 40-70 percent of all women with lower genital tract
infection (LGTI). In women lacking signs of LGTI, significantly lower percentages
of carriers of M. hominis have been reported. The occurrence of M. hominis in
healthy controls varies considerably between different studies. In general it would
seem that 5-20 percent ofall sexually active women ofchild-bearing age seem to har-
bor M. hominis. After the menopause, the incidence decreases. The proportion of
M. hominis culture-positive women is correlated to sexual experience, i.e., the car-
rier rate increases with the number ofsexual partners a person has experienced [21].
In the vast majority of women colonized by M. hominis, the vaginal smear has a
characteristic "dirty" appearance. Correlation has also been found between slight to
moderately severe dysplasia of cervical epithelial cell and colonization with M.
hominis. Antibiotic treatment resulting in the eradication of M. hominis was fol-
lowed by disappearance of the "dirty" appearance of vaginal smears [22].
The association of M. hominis with cervicitis and vaginitis is still ill-defined.
M. hominis can occur also in the upper respiratory tract, i.e., in 3-4 percent. In
persons practicing fellatio, the corresponding figure was up to almost 15 percent. In
experimental studies, M. hominis produced exudative pharyngitis [23]; however,
whether this is also the case in naturally acquired infection is not known.
Ureaplasma urealyticum
Ureaplasmas occur in the lower genital tract of the majority of women of child-
bearing age [24]. As with M. hominis, the incidence of U. urealyticum is influenced
by age, sexual activity, and hormonal status; the highest frequency is demonstrated
in pregnant women [21,24]. No significant difference in the occurrence of U.
urealyticum between women with and without signs of genital infection has been
demonstrated [24].
ASCENDANT INFECTIONS IN WOMEN WITH MYCOPLASMA HOMINIS
Isolation Studies
Both M. hominis and U. urealyticum can be recovered form the fallopian tubes
and the cul-de-sac.
A number of authors (Dienes et al. [5], Randall et al. [161, Hirsch [7], Gotthard-
son and Melen [6], and Stokes [17]) reported the recovery of PPLO in women with
PID (in some instances later identified as M. hominis) from the fallopian tubes or
tubovarian abscesses. The strain isolated by Freundt [25] represented M.fermentans
(which is a rare finding in the genital tract).
In a series of 50 women with laparoscopic signs of acute salpingitis, Mardh and
Westrom [11] found four (8 percent) to harbor M. hominis in pure culture in the
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TABLE 1
Isolation of Mycoplasma hominis from Women with Acute Salpingitis
No. (o) Culture-Positive/No. of Women Studied
Author, Publication Year
[Reference] Cervix Fallopian Tubes Cul-de-sac
M&rdh and Westrom, 1970 [11] 31(62)/50 4(8)/50 0(0)150
Eschenbach et al., 1975 [27] 14(72)/204 NS 2(4)/54
Sweet et al., 1980 [26] 11/24 0(0)/24 1(4)/24
M0ller et al., 1981 [15] 91(55)/166 NS
NS = not studied
tubes. The organism was isolated from the cervix in 31 (9 percent) of the women.
None of 34 women without laparoscopic signs of salpingitis was found to have M.
hominis. Laparoscopy, in addition to permitting sampling from the oviduct, pro-
vides an objective diagnosis of PID [3].
In another series, Sweet and co-workers [26] found one of 26 PID patients to be
culture-positive for M. hominis from cul-de-sac. Eschenbach and co-workers [27]
isolated M. hominis from the cervix of 145 of 204 women with PID. From 54 of
these 204 women samples were aspirated from cul-de-sac. M. hominis was recovered
from two of the 54 samples [15] of 166 Danish PID patients, 91 (55 percent) har-
bored M. hominis in the cervix. In another Danish study [10], 30 of 95 PID cases
had positive culture for M. hominis from the cervix. This latter study also showed
that double infections with M. hominis and other STD agents are common. The
results of some culture studies in PID patients are summarized in Table 1.
Serological Studies
Several methods have been devised to detect antibodies to M. hominis. They in-
clude complement fixation [9,14], metabolic inhibition [28], growth inhibition [29],
and indirect hemagglutination (IHA) tests [30,31]. IHA tests-performed as de-
scribed by Krogsgaard-Jensen [30]-have been found to be superior to the other
tests mentioned for detection of antibodies to M. hominis in women. A similar ex-
perience has been reported in grivet monkeys, experimentally infected with M.
hominis, which developed PID [32].
Antibodies to M. hominis as demonstrated by CF tests occurred in nine (33 per-
cent) of 27 women with PID [21], and in 20 (39 percent) of 51 women with PID [9].
IHA antibodies to the organism occurred in 28 (54 percent) of 52 women in whom
the diagnosis of PID was verified by laparoscopy, as compared to 11 percent in 56
women in whom laparoscopy showed no infectious conditions, e.g., cysts and en-
dometriosis [12]. Eschenbach et al. [27] found that 17 (22 percent) of 84 PID pa-
tients had antibodies to M. hominis. Of 60 consecutive cases with acute salpingitis,
IHA antibodies to M. hominis occurred in 24, ten of whom developed a significant
titer change [13]. Antibodies to C. trachomatis and N. gonorrhoeae occurred in 80
percent and 11 percent, respectively, of these 60 PID patients. A significant anti-
body response to these two latter organisms occurred in 20 and three women, respec-
tively [13]. In a series of 166 Danish women with PID, 23 percent showed a significant
antibody response to M. hominis. Interestingly, 14.6 percent of the 75 M. hominis
culture-negative cases also developed such an antibody response [15] (Table 2).
Increased serum levels of IgM (> 155 mg per 100 ml) was demonstrated in 18 of
53 women with salpingitis and serological evidence of a significant antibody
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Antibody Response to Mycoplasma hominis in Women with Acute PID from Whom
Consecutive Sera Were Obtained
Significant
Type of No. of Antibodies Body
Antibody Women Found Response
Author, Publication Year [Reference] Test Used Tested n (%) n (%)
Melen and Gotthardson, 1955 [14] CF 27 9(31) 4(15)
Lemcke and Csonka, 1962 [9]a CF 11 11(100) 2(18)
MArdh and Westrom, 1970 [12] IHA 29 16(55) 9(31)
Eschenbach et al., 1975 [27] MC 77 ? 17(22)
M0ller et al., 1981 [15] IHA 166 70(42) 50(30)
M&rdh et al., 1981 [13] IHA 60 24(40) 10(17)
aAll together 51 salpingitis patients were tested, using three different antigens which detect antibodies
to M. hominis in 28, 26, and 25 cases, respectively. From 11 patients, all of whom had CF antibodies
to the organism, consecutive serum samples were obtained.
CF = complement fixation; IHA = indirect hemagglutination; MC = mycoplasmacidal antibody
test
response to M. hominis [33]. There was a significant (p < 0.001) correlation be-
tween the IgM increase and the presence of serum IHA antibodies to M. hominis.
The IgM level of 200-299 itg per 100 ml was found in 11 percent and of > 300 in
seven of 53 PID cases. The maximum level was 380 mg per 100 ml. In a few cases
there was also a slight increase in the serum IgG and IgA [33].
As in M. pneumoniae infections [34] the increased IgM levels found in PID pa-
tients presumably could not be explained by the formation of antibodies specifically
directed against M. hominis. Most probably they denote an unspecific stimulation
of the immune system [331. So far, there is, however, no evidence that M. hominis
acts as a polyclonal B-cell stimulator. Antibodies to M. pneumoniae did not occur
more commonly in the PID patients than in the general population of the study area
[33]. A corresponding rise in the IgM antibody level was found in grivet monkeys ex-
perimentally infected withM. hominis, which developed parametritis rather than en-
dosalpingitis [32].
Lack ofIgM to IgG Conversion
Some patients with M. hominis-associated salpingitis did not show conversion
from essentially an IgM to an IgG antibody response to M. hominis. Persistence of
mainly IgM antibody formation was found for several months [33]. This is in con-
formity with findings in patients with M. pneumoniae [34].
Mode ofInfection Spread with Mycoplasma hominis to the Upper Genital Tract
How M. hominis ascends in the female genital tract is not known. Experiments in
grivet monkeys (see the section following), however, suggested spread via lym-
phatics and blood vessels rather than canalicularily from the uterus to the tubes [35].
EXPERIMENTAL INFECTION WITH MYCOPLASMA HOMINIS IN
MONKEYS
In grivet monekys, parametritis and salpingitis developed within three days when
M. hominis was inoculated directly into the fallopian tubes. Thus there was swelling
and hyperemia of the tubes and the parametria became edematous. The tubal
532 PER-ANDERS MARDHMYCOPLASMAL PID
subserosa was heavily infiltrated with lymphoid cells and an increased number of
polymorphonuclear leukocytes. In the parametria many lymphocytes and some
granulocytes were found, as well as fat necrosis and granulation tissue. After four to
five weeks the upper genital tract of the monkeys was virtually normal again [36].
PATHOGENETIC MECHANISMS OF MYCOPLASMA HOMINIS IN PID
In experimentally infected explants of human fallopian tubes, the mucociliary
wave activity can be registered by the light-beam reflex method [37]. Qualitative and
quantitative studies of the ciliary beating can be made. The tubal specimens are
placed in a chamber with regulated gas temperature and humidity, where they are
lighted through a glass fiber optic. The changes in the light reflexes caused by the
beating cilia are registered by a photomultiplicator. Inhibitory effects on the ciliary
activity by infection can be registered by such measurements. Infection with M.
hominis caused a reduced ciliary activity [37].
In experimentally infected explants of human tubes, M. hominis caused swelling
ofthe cilia, either ofthe tips or the entire cilia. The mechanism underlying the swell-
ing is not known. An arginine deficit in the tissue culture medium, caused by the
metabolism of M. hominis, might mediate the ciliostatic effect.
ASCENDANT INFECTIONS WITH UREAPLASMA UREALYTICUM IN
NATURALLY ACQUIRED INFECTIONS IN WOMEN AND IN EXPERIMENTAL
INFECTIONS IN MONKEYS
U. urealyticum has been recovered from the fallopian tubes [27], from cul-de-sac
of a woman with a tubovarian abscess [38], and in a woman with signs of acute sal-
pingitis [11]. A significant antibody response, i.e., of metabolic-inhibition an-
tibodies, to U. urealyticum (to a strain isolated from the fallopian tube of a PID pa-
tient) has been demonstrated in one woman with acute salpingitis [24]. Eschenbach
et al. [27] found 15 of 204 PID patients to develop ureaplasmacidal antibodies.
Sweet et al. [26] found U. urealyticum in cul-de-sac fluid in four of 26 women with
PID (also in the fallopian tubes of one of them).
In animal experiments, viz., in grivet monkeys, no pathogenic effect of U.
urealyticum was demonstrable [39]. Mycoplasmas have also been recovered from
the bovine oviduct [40]. In experimentally infected heifers, ureaplasmas and
mycoplasmas could induce damage to the oviduct mucosa [41,42].
TREATMENT OF MYCOPLASMAL PID
M. hominis is resistant to betalactam antibiotics and nitroimidazoles, which are
drugs often used in the treatment of PID.
Tetracycline has an effect against M. hominis both in vitro [43] and in vivo [44].
Minimum inhibitory concentrations (MIC) of various tetracyclines of 0.2-0.8 mg/l
have been found [43]. The corresponding values for doxycycline were 0.1-0.4 mg/l.
U. urealyticum likewise is sensitive to tetracyclines (MIC = 0.4-1.6 mg/l).
A tetracycline-resistant strain ofM. hominis was isolated from a pregnant woman
who had arrived in Sweden from Jordan the day before sampling and delivery [45].
The MIC oftetracycline for this strain was 32 mg/l. Atetracycline-resistant strain of
M. hominis could also be isolated from the cerebrospinal fluid ofher offspring, who
had signs of meningoencephalitis [45]. Strains of U. urealyticum with a decreased
susceptibility to tetracycline have also been reported to be relatively common.
M. hominis generally can be eradicated from the female genital tract by a stan-
dard course of tetracycline for one or two weeks [44]. This is in contrast to U.
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urealyticum, which often persists after standard courses with tetracycline. Thus the
organism has been found in up to one-third of the patients given such therapy [44].
In contrast to M. hominis, U. urealyticum is susceptible to erythromycin (MIC =
0.2-0.8 mg/l) [43].
In the case of deep, complicated genital infections and in systemic infections by
M. hominis, at least two weeks of tetracycline treatment should be given.
The risk that M. hominis can spread to the newborn infant, resulting in infections
of the skin [46,47], the eyes [48], and the central nervous system [45], must not be
disregarded.
SEQUELAE OF MYCOPLASMAL PID
No studies have so far been presented concerning sequelae of PID stratified with
regard to the major common etiological agents of PID, including M. hominis. The
risk of sterility after PID is known to be high-roughly 10-15 percent after one
episode of the disease, 35 percent after two, and 75 percent after three or more such
episodes [1]. Chronic abdominal pain and increased risk for etopic pregnancy [49]
are other common sequelae after PID. Whether such sequelae also occur after M.
hominis-associated PID is not known.
CHALLENGES FOR FUTURE RESEARCH
Further studies on antigenic differences [50] among organisms now classified as
M. hominis ought to be performed.
More epidemiological data concerning M. hominis infections of the upper genital
tract are required. So far, most epidemiological reports have derived from the Scan-
dinavian countries or from the U.S.
Whether there is a discrepancy between findings in grivet monkeys experimentally
infected with M. hominis and naturally infected human beings with PID remains to
be determined. In the monkeys, the parametria rather than the fallopian tubes seem
to be affected.
Clinical observations indicate also that the parametria might be involved in PID in
women who are culture-positive for M. hominis and in whom a significant antibody
response to the organism can be demonstrated. Furthermore, a biopsy of the
parametria of such a woman revealed similar inflammatory changes as those seen in
monkeys experimentally infected by M. hominis [M0ller BR: personal communica-
tion]. Further clinical studies on parametritis are required.
More studies are also needed to establish pathogenetic mechanisms in M. hominis
infections, including PID.
Finally, possible sequelae of mycoplasmal PID must be further studied.
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